All In Biotech

Drug Trial Radar · NCT07826052

Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer

A Prospective, Open-Label, Single-Arm Phase II Clinical Trial to Explore Chemotherapy Exemption in Elderly Women Aged 65 Years or Older With Lymph Node-Positive ER+/HER2- Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

494

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Sep 30, 2031

Study completion Oct 1, 2035

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, multicenter, single-arm Phase II clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged \>65 years) with lymph node-positive, HR+/HER2- breast cancer.

Conditions

  • Breast Cancer
  • Adjuvant Therapy

Interventions

  • CDK4/6 inhibitorDrug

    (abemaciclib/ribociclib/dalpiciclib/palbociclib)

  • Endocrine Therapy (Optional)Drug

    Endocrine therapy (letrozole/anastrozole/exemestane)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 5-years Invasive disease free survivalTime frame: 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.